OKYO Pharma Limited - PDMR Dealing
OKYO Pharma Limited - PDMR Dealing
LONDON and BOSTON, May 20, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), a life sciences company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain, today announces that it has been notified that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman has a beneficial interest, purchased 5,800,000 ordinary shares of no par value ("Ordinary Shares") at a price of £0.0625 each (which would be equivalent to the purchase of 89,230 of the Company's ADSs on NASDAQ at a price of US$5.08 per ADS).
The acquisition would have increased Mr Cerrone's beneficial interests in the capital of the Company from 39.64% to 40.06%, however the impact of the offering which closed yesterday, reduces these holdings to, in aggregate, 39.08% after allowing for; (i) the dilutive effect of the Ordinary Shares to be issued in the Offering; and (ii) the 25,000 ADS (representing 1,625,000 Ordinary Shares) purchased by Mr Cerrone in the Offering).
|
1. |
Details of PDMR / person closely associated |
|
|
a) |
Name |
Gabriele Cerrone |
|
2. |
Reason for the notification |
|
|
a) |
Position / status |
Chairman |
|
b) |
Initial notification /amendment |
Initial notification |
|
3. |
Details of the issuer |
|
|
a) |
Name |
OKYO Pharma Limited |
|
b) |
LEI |
213800VVN5CB56Y15A05 |
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|
|
a) |
Description of the financial instrument |
Ordinary Shares of no par value |
|
b) |
Identification code of the Financial Instrument |
ISIN for OKYO Pharma Limited GG00BD3FV870 |
|
c) |
Nature of the transaction |
Market Purchase |
|
d) |
Price(s) and volume(s) |
£0.0625 - 5,800,000 |
|
f) |
Date of the transaction |
19 May 2022 |
|
g) |
Place of the transaction |
XLON |
Enquiries:
|
OKYO Pharma Limited |
Gary S. Jacob, Chief Executive Officer |
+44 (0)20 7495 2379 |
Editor Details
-
Company:
- PharmiWeb.com
-
Name:
- PW Editor
- Email:
-
Telephone:
- +441344851506
